Weight ManagementAlso known as: LY3305677, IBI362
Mazdutide
Next-generation dual GLP-1/glucagon receptor agonist developed by Innovent Biologics — approved in China (2024) for obesity. Shows ~15% body weight reduction in Phase 3.
Half-Life
~6-7 days
Dose Range
3-9 mg/week
Frequency
1× every 2 weeks
Vial Sizes
3 mg, 6 mg, 9 mg
Mechanism of Action
Dual agonist peptide that simultaneously activates GLP-1 receptors (appetite suppression, insulin secretion) and glucagon receptors (hepatic lipid oxidation, energy expenditure increase). The glucagon component adds thermogenic fat burning absent in pure GLP-1 agonists.
Source: PMID: 37578886
Dosing Protocol
| Typical Dose | 3-9 mg/week |
| Frequency | 1× every 2 weeks |
| Half-Life | ~6-7 days |
| Common Vial Sizes | 3 mg, 6 mg, 9 mg |
Reconstitution Example
Vial
6 mg
Water
2 mL
Concentration
3 mg/mL
Per Unit (100u syringe)
30 mcg
Dose of 3000 mcg = 100 units on a 100-unit insulin syringe
Dosing Quick Reference
Mazdutide— Dosing Guide
Dose Range
3-9 mg/week
Half-Life
~6-7 days
Frequency
1× every 2 weeks
Route
Subcutaneous
3 mg vial6 mg vial9 mg vial
💧 2 mL BAC water|📐 3 mg/mL concentration|💉 30 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code